Stocks News

LAST PRICE
15.5600
TODAY'S CHANGE (%)
Trending Up0.0600 (0.3871%)

Bid / Lots
15.0400/ 6
Ask / Lots
15.6800/ 1
Open / Previous Close
15.2400 / 15.5000
Day Range
Low 15.0700
High 16.0000
52 Week Range
Low 12.9500
High 20.3100
Volume
590,512
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 30, 2024
- Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting, from 9:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  9:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: RCUS
  
  Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
  -- Data, including overall survival, from ARC-10, a randomized study evaluating domvanalimab plus zimberelimab in front-line, PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC), will be presented in a late-breaking poster presentation -- An oral presentation will highlight data from an Investigator Sponsored Trial for domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma, demonstrating further proof of concept for the Fc-silent anti-TIGIT antibody domvanalimab -- Arcus will discuss the ARC-10 results in more detail on its earnings call at 2:00 PM PT / 5:00 PM ET on Wednesday, November 6, 2024 HAYWARD, Calif.--(BUSINESS WIRE)--October 30, 2024--
Oct 25, 2024
- DJ Arcus Biosciences Is Maintained at Overweight by Barclays, from 1:42PM ET on Friday Oct 25, 2024 by Dow Jones
  1:42PM ET on Friday Oct 25, 2024 by Dow Jones
  Companies Mentioned: RCUS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RCUS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 25, 2024 13:42 ET (17:42 GMT)
Oct 24, 2024
- Arcus Biosciences Announces New Employment Inducement Grants, from 4:35PM ET on Thursday Oct 24, 2024 by Dow Jones
  4:35PM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: RCUS
  
  Arcus Biosciences Announces New Employment Inducement Grants
  HAYWARD, Calif.--(BUSINESS WIRE)--October 24, 2024--
  Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Company's common stock at an exercise price per share of $17.33, which was the closing price on October 23, 2024, and restricted stock units to acquire a total of 14,300 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.
- DJ Arcus Biosciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co., from 3:31PM ET on Thursday Oct 24, 2024 by Dow Jones
  3:31PM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: RCUS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RCUS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 24, 2024 15:31 ET (19:31 GMT)
- Arcus Biosciences Reports 'Encouraging' First Data for Casdatifan in Patients With Metastatic Kidney Cancer, from 9:28AM ET on Thursday Oct 24, 2024 by MT Newswires
  9:28AM ET on Thursday Oct 24, 2024 by MT Newswires
  Companies Mentioned: RCUS
  09:28 AM EDT, 10/24/2024 (MT Newswires) -- Arcus Biosciences (RCUS) reported "encouraging" first clinical data Thursday from a phase 1/1b study evaluating casdatifan in metastatic clear cell renal cell carcinoma, which is a type of kidney cancer. Th...

Yesterday
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: TVTX
- Travere Therapeutics to Present at Upcoming Investor Conferences, from 9 hours ago by Dow Jones
  9 hours ago by Dow Jones
  Companies Mentioned: TVTX
- DJ Ardelyx Is Maintained at Buy by Citigroup, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: ARDX
- DJ Vir Biotechnology Is Maintained at Overweight by Barclays, from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: VIR
- DJ Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co., from 19 hours ago by Dow Jones
  19 hours ago by Dow Jones
  Companies Mentioned: VIR
Nov 2, 2024
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX, from 12:01PM ET on Saturday Nov 02, 2024 by PR Newswire
  12:01PM ET on Saturday Nov 02, 2024 by PR Newswire
  Companies Mentioned: TVTX
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX, from 12:00PM ET on Saturday Nov 02, 2024 by Dow Jones
  12:00PM ET on Saturday Nov 02, 2024 by Dow Jones
  Companies Mentioned: TVTX
Nov 1, 2024
- DJ Ardelyx Price Target Maintained With a $11.00/Share by HC Wainwright & Co., from 4:19PM ET on Friday Nov 01, 2024 by Dow Jones
  4:19PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: ARDX
- DJ Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates, from 3:05PM ET on Friday Nov 01, 2024 by Dow Jones
  3:05PM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: SNY, VIR
- DJ Travere Therapeutics Is Maintained at Sector Outperform by Scotiabank, from 11:01AM ET on Friday Nov 01, 2024 by Dow Jones
  11:01AM ET on Friday Nov 01, 2024 by Dow Jones
  Companies Mentioned: TVTX

Arcus Biosciences Inc
NYSE:RCUSUnited States

Search Criteria

Oct 30, 2024

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting, from 9:00AM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 25, 2024

DJ Arcus Biosciences Is Maintained at Overweight by Barclays, from 1:42PM ET on Friday Oct 25, 2024 by Dow Jones

Oct 24, 2024

Arcus Biosciences Announces New Employment Inducement Grants, from 4:35PM ET on Thursday Oct 24, 2024 by Dow Jones

DJ Arcus Biosciences Price Target Maintained With a $20.00/Share by HC Wainwright & Co., from 3:31PM ET on Thursday Oct 24, 2024 by Dow Jones

Arcus Biosciences Reports 'Encouraging' First Data for Casdatifan in Patients With Metastatic Kidney Cancer, from 9:28AM ET on Thursday Oct 24, 2024 by MT Newswires

Peers Headlines

Yesterday

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX, from 9 hours ago by Dow Jones

Travere Therapeutics to Present at Upcoming Investor Conferences, from 9 hours ago by Dow Jones

DJ Ardelyx Is Maintained at Buy by Citigroup, from 13 hours ago by Dow Jones

DJ Vir Biotechnology Is Maintained at Overweight by Barclays, from 18 hours ago by Dow Jones

DJ Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co., from 19 hours ago by Dow Jones

Nov 2, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX, from 12:01PM ET on Saturday Nov 02, 2024 by PR Newswire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX, from 12:00PM ET on Saturday Nov 02, 2024 by Dow Jones

Nov 1, 2024

DJ Ardelyx Price Target Maintained With a $11.00/Share by HC Wainwright & Co., from 4:19PM ET on Friday Nov 01, 2024 by Dow Jones

DJ Vir Shares Rally 25% on Cancer Licensing Deal With Sanofi, Trial Updates, from 3:05PM ET on Friday Nov 01, 2024 by Dow Jones

DJ Travere Therapeutics Is Maintained at Sector Outperform by Scotiabank, from 11:01AM ET on Friday Nov 01, 2024 by Dow Jones